|
|
 FDA Information - November 20, 2008
| Worried about health effects, on Tuesday, public health and environmental groups asked the Food and Drug Administration to remove from the market widely used household products that contain the germ fighting chemical triclosan. Scientific studies dispute the need for the chemical and link its widespread use to health and environmental effects and the development of stronger bacteria that are increasingly difficult to control | | Researchers are in California are about to start the first FDA-sanctioned clinical trial of a stem cell treatment for a brain disease. The recipients will be children who have Batten disease - a rare, fatal genetic disorder. The condition afflicts 2 to 4 of every 100,000 children born in the U.S. Babies may appear normal at first, only to begin losing coordination and having seizures several months after birth. Eventually, children go blind and are unable to communicate before they die at an early age | | New anaylsis finds a diabetes pill, on its way toward federal approval, doubles the risks of deaths, heart attacks and strokes. Muraglitazar, to be sold under the name Pargluva for treatment of Type 2 diabetes, was endorsed by a Food and Drug Administration panel last month. Researchers with the Cleveland Clinic analyzed the data on the drug, developed by Bristol-Myers Squibb and Merck & Co., which the FDA made public before the panel vote | | "Our research shows that consumers are familiar with Clean, Separate, Cook and Chill, the core Fight BAC! food safety recommendations, but they need more guidance about how to do these properly," says Partnership for Food Safety Education Chairman, Tim Hammonds | |
Hector Duarte Jr. - All Headline News Staff Reporter In a letter to acting FDA Commissioner Dr. Andrew von Eschenbach, the members of Congress practically accuse the agency of earlier postponing a ruling because of politics | |
|
|
